



# Contrasting evolution of virulence and replication rate in an emerging bacterial pathogen

Luc Tardy<sup>a</sup>, Mathieu Giraudeau<sup>a,b,1</sup>, Geoffrey E. Hill<sup>c</sup>, Kevin J. McGraw<sup>b</sup>, and Camille Bonneaud<sup>a,2</sup>

<sup>a</sup>Centre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE Cornwall, United Kingdom; <sup>b</sup>School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501; and <sup>c</sup>Department of Biological Sciences, Auburn University, Auburn, AL 36849-5414

Edited by Robert E. Ricklefs, University of Missouri–St. Louis, St. Louis, MO, and approved July 10, 2019 (received for review February 21, 2019)

**Host resistance through immune clearance is predicted to favor pathogens that are able to transmit faster and are hence more virulent. Increasing pathogen virulence is, in turn, typically assumed to be mediated by increasing replication rates. However, experiments designed to test how pathogen virulence and replication rates evolve in response to increasing host resistance, as well as the relationship between the two, are rare and lacking for naturally evolving host–pathogen interactions. We inoculated 55 isolates of *Mycoplasma gallisepticum*, collected over 20 y from outbreak, into house finches (*Haemorrhous mexicanus*) from disease-unexposed populations, which have not evolved protective immunity to *M. gallisepticum*. We show using 3 different metrics of virulence (body mass loss, symptom severity, and putative mortality rate) that virulence has increased linearly over >150,000 bacterial generations since outbreak (1994 to 2015). By contrast, while replication rates increased from outbreak to the initial spread of resistance (1994 to 2004), no further increases have occurred subsequently (2007 to 2015). Finally, as a consequence, we found that any potential mediating effect of replication rate on virulence evolution was restricted to the period when host resistance was initially increasing in the population. Taken together, our results show that pathogen virulence and replication rates can evolve independently, particularly after the initial spread of host resistance. We hypothesize that the evolution of pathogen virulence can be driven primarily by processes such as immune manipulation after resistance spreads in host populations.**

bacteria | emerging infectious disease | evolution of resistance | evolution of virulence | pathogen load

Understanding the evolution of pathogen virulence in response to host resistance is central to predicting and managing pathogenesis (1–3). Current theory predicts a positive association between the evolution of host immunity and the evolution of pathogen virulence (4–9), with the common assumption that this positive association is underpinned by increasing replication rates in response to host resistance (5, 6, 8, 10–15). However, experimental tests of the impacts of host resistance on the evolution of pathogen virulence and replication rates, as well as the relationship between the two, remain exceptional (2, 16, 17).

In laboratory tests, host resistance can be manipulated through either vaccination with a recombinant antigen or whole-parasite immunization, with pathogen responses quantified after passage through resistant versus susceptible hosts. Using such approaches, the rodent malaria model *Plasmodium chabaudi* was shown to evolve increased virulence when repeatedly passed through either vaccinated or immunized mice (16, 17). Parasite densities, however, only increased in vaccinated mice, with the faster growing parasites being the more virulent. Whether differences in the effectiveness of the immune responses elicited can explain differences between these findings is unknown. Regardless, these studies demonstrate that experimental increases in host resistance can drive virulence evolution, as predicted by theory; however, for some reason, this association only emerges from increased replication rates in vaccinated hosts (16, 17).

Field tests of the impacts of host resistance on pathogen virulence and replication rates are more challenging because there are few host–pathogen systems for which we have documented natural changes in host resistance and associated changes in pathogen virulence over time (18–21). Furthermore, nonresistant hosts are rarely available, but such hosts are essential for controlled experiments because changes in pathogen traits need to be measured experimentally in the absence of the confounding effects of immune activity and clearance (22). One of the few systems in which pathogens evolving in hosts of changing resistance were compared in nonresistant hosts was the myxomatosis outbreak in introduced European rabbits (*Oryctolagus cuniculus*) in Australia (21). In this case, experimental inoculation of nonresistant laboratory rabbits with 3 viral isolates collected at outbreak (in the 1950s) and 15 isolates collected >40 y later (i.e., after rabbits had become resistant) showed that virulence increased following the spread of genetic resistance (22). However, whether virulence has increased linearly or nonlinearly over time and whether increased virulence was driven by increased replication rates were not clarified.

One way of addressing these issues is to contrast measures of virulence and replication rates in a large number of distinct pathogen isolates encompassing the period before, during, and after the spread of host resistance. Here, we do so in an infection

## Significance

**With increasing antibiotic resistance, there is a pressing need to understand how host resistance naturally influences bacterial virulence and replication rates. We test this in an infection experiment using 55 isolates of a bacterium, which were collected over the course of the epidemic following its natural emergence in a North American songbird. We demonstrate virulence has increased linearly from outbreak to the present day, encompassing >150,000 bacterial generations. Despite this, bacterial replication rate only increased during the initial spread of host resistance but not thereafter. Thus, contrary to common assumptions, virulence and replication rates can evolve independently, particularly after the initial spread of host resistance.**

Author contributions: C.B. designed research; L.T., M.G., K.J.M., and C.B. performed research; G.E.H. contributed new reagents/analytic tools; C.B. analyzed data; and C.B. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

Data deposition: Data reported in this paper have been deposited in Dryad Digital Repository ([doi:10.5061/dryad.km3109k](https://doi.org/10.5061/dryad.km3109k)).

<sup>1</sup>Present address: Centre for Ecological and Evolutionary Research on Cancer, Unité Mixte de Recherche Centre National de la Recherche Scientifique/Institut de Recherche pour le Développement/Université de Montpellier 5290 Maladies Infectieuses et Vecteurs Ecologie, Génétique, Evolution et Contrôle (MIVEGEC), 34394 Montpellier, France.

<sup>2</sup>To whom correspondence may be addressed. Email: [c.bonneaud@exeter.ac.uk](mailto:c.bonneaud@exeter.ac.uk).

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1901556116/-DCSupplemental](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1901556116/-DCSupplemental).

Published online August 1, 2019.







**Table 1. Summary of relationships between metrics of virulence and replication rates over the course of the epidemic**

Model	Estimate $\pm$ SE	Statistics	P	R <sup>2</sup>
1. Response: body mass change				
Replication rate	$<-0.01 \pm <0.01$	$t_{52} = -0.7$	0.48	0.02
Replication rate <sup>2</sup>	$0.3 \pm 1.0$	$t_{51} = 0.4$	0.72	0.02
Replication rate $\times$ sampling period	$-0.03 \pm 0.03$	$t_{50} = -1.0$	0.31	0.08
2. Response: mean conjunctival swelling				
Replication rate	$0.13 \pm 0.31$	$t_{43} = 0.4$	0.66	0.02
Replication rate <sup>2</sup>	$-27.6 \pm 19.8$	$t_{42} = -1.4$	0.17	0.06
Replication rate $\times$ sampling period	$1.4 \pm 0.7$	$t_{41} = 2.0$	<b>&lt;0.05</b>	<b>0.25</b>
3. Response: survival probability				
Replication rate	$0.07 \pm 0.04$	$z = 1.6$	0.10	
Replication rate <sup>2</sup>	$-1.1 \pm 2.4$	$z = -0.5$	0.64	
Replication rate $\times$ sampling period	$0.03 \pm 0.09$	$z = 0.3$	0.74	

The sampling period was categorized as before (1994 to 2004) versus after (2007 to 2015) the spread of host resistance. The single significant effect is provided in boldface.


Pathogen virulence is assumed to be mediated primarily through variation in pathogen replication rates (11, 13, 14, 39), so much so that pathogen load has been used as a surrogate for virulence (40). Despite this, current evidence for a tight link between replication rates and virulence is mixed (10, 14, 16, 17, 41–43). For variation in the replication rates of *M. gallisepticum* to mediate variation in virulence, both variables (replication rate and virulence) need to show equivalent patterns of response over time as hosts evolve resistance. On the contrary, however, while virulence shows a linear increase over the course of the epidemic, this is not the case for our measures of replication rate, which all showed an increase between disease outbreak and the initial spread of host resistance, but not thereafter. In other words, our measures of replication rate showed a quadratic, not linear, relationship with year of pathogen sampling. Further experiments are required to fully understand the basis of these quadratic relationships between year of pathogen sampling and replication rate or pathogen load, but there are 2 likely hypotheses for what we observed. First, replication rates may have already been optimized for pathogen transmission by the time host resistance spread in the population, with insufficient subsequent selection to drive the evolution of further increases. Alternatively, following the initial spread of host resistance, selection might have primarily operated on other fitness-maximizing traits in the pathogen, which are antagonistic to further increases in replication rates. Either way, our results suggest that replication rate is not the primary driver of the evolution of increasing virulence in *M. gallisepticum*, especially following the initial spread of resistance in house finches.

The weak associations between metrics of virulence and replication rates suggest that another pathogen trait, in addition to replication rate, accounts for significant variation in virulence. One likely candidate is the ability to manipulate the host immune system (44, 45). Evidence suggests that immune manipulation is critical to the success of *M. gallisepticum* infection (46–49). First, *M. gallisepticum* invades the mucosal surfaces of the conjunctiva and upper respiratory tract by inducing a misdirected inflammatory response, with more virulent strains inducing greater responses (46, 47, 50–55). For example, chickens experimentally inoculated with a virulent strain of *M. gallisepticum* ( $R_{low}$ ) display greater up-regulation of proinflammatory cytokines, which are responsible for local and systemic inflammation, and associated tissue destruction and local necrosis, than chickens inoculated with a more attenuated strain (GT5) (56). Second, the subsequent persistence of *M. gallisepticum* then depends on the bacterium's ability to evade and suppress other immune components known to play a role in controlling *M. gallisepticum* infection (54). For example, chickens infected with *M. gallisepticum* display lower T cell activity 2 wk postinoculation than controls (52, 53), as well as lower humoral responses against other pathogens (57, 58). Similarly, we have shown previously that house finches from

unexposed populations are unable to up-regulate the expression of genes associated with acquired immunity (cell-mediated immunity), again consistent with persistence being facilitated by the suppression of protective immune processes (18, 28). Finally, between-host transmission occurs through eye droplets transferred directly or left on inert surfaces as fomites, which are produced as ocular secretions resulting from inflammation (59). Thus, while the suppression of pathogen-specific immune processes is required for *M. gallisepticum* persistence, the up-regulation of nonspecific, damaging inflammatory processes is required for successful pathogen colonization and transmission. In this system, it therefore seems reasonable to hypothesize that there is independent selection on virulence and replication rate, leading to linear increases in the former, but not in the latter, over the course of the epidemic.

Our results have at least 4 important implications for host–pathogen interactions:

- 1) Increasing host resistance has given rise to linear increases in pathogen virulence, at least over the estimated >150,000 bacterial generations encompassed in this study.
- 2) By contrast, replication rates appear to have been under directional selection between pathogen outbreak and the initial spread of resistance, but not thereafter.
- 3) As a consequence, virulence evolution and replication rates can be under independent selection pressures, and the potentially



**Fig. 3.** Association between replication rates (ratio of pathogen cells to host cells per day) and virulence, as measured by mean conjunctival swelling (in pixels). We show the association for pathogen isolates sampled before (in gray) versus after (in black) the spread of host resistance. Points represent raw values; lines are predicted from the model (dashed lines, isolates sampled pre-resistance; solid lines, isolates sampled post-resistance), with SEs represented by ribbons. None of the other analyses investigating the relationship between replication rate and other measures of virulence was significant (Table 1).

weak associations between the 2 suggest that replication rates should not be used as a metric of virulence.

- 4) Finally, we hypothesize that selection on immune manipulation is dominant over that on replication rate following the initial spread of host resistance, but this hypothesis remains to be tested in this and other systems.

## Methods

**Capture and Housing.** Wild house finches from populations that have never been exposed to *M. gallisepticum* (i.e., that have not evolved genetic resistance) were captured in variety of urban and suburban sites in Arizona in the summer of 2015 ( $n = 57$ , 30 males and 27 females). *M. gallisepticum* has never been recorded in the sampling area despite continuous monitoring (60). Using birds that have not had the opportunity to evolve protective immune responses to *M. gallisepticum* is essential for measuring genetically determined virulence and replication rate in the pathogen without the confounds of the capacity for immune clearance (22). There is currently no evidence in this or any other system to suggest that genetically determined levels of virulence and replication rate are modified by differences in host resistance, but our ability to measure each will obviously be curtailed if done so in resistant hosts. Birds that had hatched in the spring of 2015 were trapped, weighed, and banded with a numbered metal tag for individual identification. They were then immediately transported by car to indoor aviaries at Arizona State University's Tempe campus, where they were housed for the remainder of the experiment. On arrival, we obtained a blood sample from all birds using brachial venipuncture (60  $\mu$ L of whole blood) and a choanal swab. A lack of prior infection with *M. gallisepticum* since hatching was confirmed by screening blood plasma for anti-*M. gallisepticum* antibodies using a serum plate agglutination assay (61), and a lack of current infection was verified using the choanal swabs in PCR amplification of *M. gallisepticum* DNA (62).

**Experimental Inoculation.** Each of the 55 *M. gallisepticum* isolates sampled over the course of the epidemic was inoculated into 1 bird selected at random from the 57, although 2 isolates (1 each from 1995 and 2007) were inoculated in 2 birds. Maximizing the number of pathogen isolates used is essential for clarifying the shape of the relationship between pathogen traits and time in a regression-based statistical approach (33, 34). The alternative of using fewer isolates replicated across multiple hosts would be more appropriate to fully characterize differences among pathogen isolates, but that was not the aim of the study. Further, evidence of evolution requires systematic changes in trait values over time that are observable against random background variation in ecology. In the context of our study, this random ecological variation is represented by inevitable slight among-host variation in the response to infection (although recall that none of the birds used has evolved resistance). By randomly pairing each bird with a distinct pathogen isolate (but occasional exceptions are discussed above), any slight variation in host responses to infection will be randomly distributed over the years of pathogen sampling. Thus, while the precise value of a given point will likely include some impact of host response, the shape of the regression slopes of pathogen traits over time will reflect the patterns of pathogen evolution. Finally, isolates were obtained over a 20-y period at random from naturally infected, wild-caught house finches from various urban and suburban sites in 8 different states in the eastern United States (mainly from Alabama). Given that *M. gallisepticum* requires inducing symptoms for successful transmission, our isolates are therefore a representative sample of those successfully circulating within the host population at a given time.

Isolates were obtained by swabbing the conjunctiva of a symptomatic bird and placing the swab in SP4 growth medium. Isolates were administered via 20  $\mu$ L of culture containing  $1 \times 10^4$  to  $1 \times 10^5$  color-changing units per milliliter of *M. gallisepticum* in both eyes. Later quantification of the number of bacterial cells in each inoculum was determined using qPCR (discussed below), and concentrations of the inoculums were found to range from  $4.1 \times 10^5$  to  $3.0 \times 10^6$  bacterial cells per microliter (average  $\pm$  SE =  $1.4 \times 10^6 \pm 0.6 \times 10^6$  bacterial cells per microliter). To account for any variation in the number of bacterial cells inoculated (i.e., dose), we verified that there was no correlation between dose and year of sampling of the isolate (Spearman's rank correlation:  $P = 0.49$ ), and we included dose as a covariate in all our analyses (Statistical Analyses). None of the isolates had been passaged in culture more than 3 times (63). All 57 birds were maintained individually in separate cages with ad libitum food and water from the time they were inoculated and throughout the duration of the 34-d experiment. The experiment was stopped at 35 dpi, and all birds were euthanized as stipulated by home office licensing. Protocols were approved by Institutional Animal Care and

Use Committees of Arizona State University (permit 15-1438R), as well as by Institutional Biological Use Authorizations to Auburn University (BUA 500), and by the University of Exeter's Ethics Committee.

**Symptom Severity.** We have shown previously that mass loss is indicative of the severity of infection in nonresistant birds from unexposed populations, and so can be used as a measure of virulence (64). All birds were weighed ( $\pm 0.01$  g) at the start and end of the experiment using a top-pan balance. To quantify the size of the conjunctiva, and so the severity of conjunctival swelling, we photographed the right and left eyes at 0, 6, 13, and 25 dpi from a standardized distance. We then measured the average area of the conjunctiva swelling across the 2 eyes and at each day as follows: the area of the outer ring minus the area of the inner ring at 6, 13, or 25 dpi – the area of the outer ring minus the area of the inner ring at 0 dpi (65). Measurements of photographs were done blindly with respect to the isolate inoculated. Finally, eyes were also inspected visually on days 3, 6, 8, 14, 21, 25, 28, and 34 postinfection: Infection is considered lethal when the conjunctiva is red to purple and the eye is difficult to see and produces discharge. Such symptoms, with little or no vision possible, are thought to have caused the death of millions of infected finches due to starvation or predation (25, 35, 62).

**Bacterial Load.** Bacterial load was measured from conjunctival and tracheal swabs obtained at 8, 14, 21, and 28 dpi by quantifying the number of *M. gallisepticum* *mgc2* gene copies and the number of house finch *rag1* gene copies using a redesigned qPCR assay (assay design, validation, and details are shown in *SI Appendix, Tables S1 and S2*). Pathogen load was then determined as the number of *M. gallisepticum* cells divided by the number of house finch cells to control for variation in sampling efficiency (66). DNA was extracted using a QIAGEN DNeasy Blood and Tissue Kit according to the manufacturer's standard protocols.

**Statistical Analyses.** All statistical analyses were conducted in R version 3.3.2 (67), and figures were made using ggplot2 (68). We verified that any variation in the number of bacterial cells inoculated (i.e., dose) did not confound our results. There was no correlation between the dose inoculated and the year of pathogen sampling (as discussed above), and dose was not a significant covariate in any of our analyses (all  $P > 0.5$ ). These results show that any slight variation in dose inoculated was not systematically biased toward isolates of high virulence, and that it was not sufficient to confound any of our results.

**Virulence.** Analyses of mass loss and conjunctival swelling were conducted using linear models with normal error structures, with dose inoculated and year of pathogen sampling fitted as fixed terms. For changes in body mass, we also included initial body mass at inoculation as a covariate. Putative survival probability over time was analyzed using a log-rank test with year of pathogen sampling and dose inoculated as explanatory terms. Further, differences in temporal changes in survival probability from outbreak to the spread of host resistance versus an equivalent period of time after resistance had spread were modeled using a logistic regression with survival (0/1) as the response variable, and with year of pathogen sampling, sampling period (pre- vs. postresistance), their interaction, and dose inoculated as explanatory terms. **Pathogen load and replication rate.** Most isolates achieved a low pathogen load and showed relatively low rates of replication, although some displayed substantial levels of each. As a consequence, these data followed a negative binomial distribution, and so were analyzed using generalized linear models with negative binomial error structures and logarithm link functions (69, 70), and with dose inoculated, year of pathogen sampling, and year of pathogen sampling<sup>2</sup> fitted as fixed terms. It is important to note that such log-link functions do not log-transform the response term, but exponentiate the explanatory term. As such, quadratic relationships between year of pathogen sampling and measures of pathogen load and replication rate are not expected by chance in these models.

**Association between replication rate and virulence.** To test for associations between replication rates and virulence, we ran linear models with either body mass change or conjunctival swelling as the response variable and logistic regressions with survival (0/1) as the response variable. Potential explanatory terms included were replication rate, replication rate<sup>2</sup>, and the interaction between replication rate and sampling period (pre- vs. postresistance). Dose inoculated was fitted as a covariate, but this was never significant.

**ACKNOWLEDGMENTS.** We thank A. Buckling, A. Russell, B. Longdon, the handling editor, and 2 anonymous referees for helpful discussion and/or constructive comments on the manuscript. We thank M. Staley for growing and shipping the pathogen isolates, M. Cooke for assisting with bird captures, and A. K. Ziegler for assisting with the experiment. This research was supported by Natural Environment Research Council Standard Grant NE/M00256X (to C.B.).

1. M. Boots, The need for evolutionarily rational disease interventions: Vaccination can select for higher virulence. *PLoS Biol.* **13**, e1002236 (2015).
2. A. F. Read *et al.*, Imperfect vaccination can enhance the transmission of highly virulent pathogens. *PLoS Biol.* **13**, e1002198 (2015).
3. O. Restif, Evolutionary epidemiology 20 years on: Challenges and prospects. *Infect. Genet. Evol.* **9**, 108–123 (2009).
4. S. Alizon, A. Hurford, N. Mideo, M. Van Baalen, Virulence evolution and the trade-off hypothesis: History, current state of affairs and the future. *J. Evol. Biol.* **22**, 245–259 (2009).
5. R. M. Anderson, R. M. May, Coevolution of hosts and parasites. *Parasitology* **85**, 411–426 (1982).
6. P. W. Ewald, Host-parasite relations, vectors, and the evolution of disease severity. *Annu. Rev. Ecol. Syst.* **14**, 465–485 (1983).
7. S. Gandon, M. J. Mackinnon, S. Nee, A. F. Read, Imperfect vaccines and the evolution of pathogen virulence. *Nature* **414**, 751–756 (2001).
8. S. Gandon, Y. Michalakis, Evolution of parasite virulence against qualitative or quantitative host resistance. *Proc. Biol. Sci.* **267**, 985–990 (2000).
9. T. C. Porco, J. O. Lloyd-Smith, K. L. Gross, A. P. Galvani, The effect of treatment on pathogen virulence. *J. Theor. Biol.* **233**, 91–102 (2005).
10. J. C. de Roode, A. J. Yates, S. Altizer, Virulence-transmission trade-offs and population divergence in virulence in a naturally occurring butterfly parasite. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 7489–7494 (2008).
11. D. Ebert, Experimental evolution of parasites. *Science* **282**, 1432–1435 (1998).
12. H. M. Ferguson, M. J. Mackinnon, B. H. Chan, A. F. Read, Mosquito mortality and the evolution of malaria virulence. *Evolution* **57**, 2792–2804 (2003).
13. S. A. Frank, Models of parasite virulence. *Q. Rev. Biol.* **71**, 37–78 (1996).
14. C. Fraser, T. D. Hollingsworth, R. Chapman, F. de Wolf, W. P. Hanage, Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 17441–17446 (2007).
15. T. J. Little, W. Chadwick, K. Watt, Parasite variation and the evolution of virulence in a *Daphnia*-microparasite system. *Parasitology* **135**, 303–308 (2008).
16. V. C. Barclay *et al.*, The evolutionary consequences of blood-stage vaccination on the rodent malaria *Plasmodium chabaudi*. *PLoS Biol.* **10**, e1001368 (2012).
17. M. J. Mackinnon, A. F. Read, Immunity promotes virulence evolution in a malaria model. *PLoS Biol.* **2**, E230 (2004).
18. C. Bonneaud *et al.*, Rapid evolution of disease resistance is accompanied by functional changes in gene expression in a wild bird. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 7866–7871 (2011).
19. P. Elsworth *et al.*, Increased virulence of rabbit haemorrhagic disease virus associated with genetic resistance in wild Australian rabbits (*Oryctolagus cuniculus*). *Virology* **464–465**, 415–423 (2014).
20. D. M. Hawley *et al.*, Parallel patterns of increased virulence in a recently emerged wildlife pathogen. *PLoS Biol.* **11**, e1001570 (2013).
21. P. J. Kerr *et al.*, Myxoma virus and the Leporipoxviruses: An evolutionary paradigm. *Viruses* **7**, 1020–1061 (2015).
22. P. J. Kerr *et al.*, Next step in the ongoing arms race between myxoma virus and wild rabbits in Australia is a novel disease phenotype. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 9397–9402 (2017).
23. N. F. Delaney *et al.*, Ultrafast evolution and loss of CRISPRs following a host shift in a novel wildlife pathogen, *Mycoplasma gallisepticum*. *PLoS Genet.* **8**, e1002511 (2012).
24. A. A. Dhondt, D. L. Tessaglia, R. L. Slothower, Epidemic mycoplasmal conjunctivitis in house finches from eastern North America. *J. Wildl. Dis.* **34**, 265–280 (1998).
25. J. S. Adelman, C. Mayer, D. M. Hawley, Infection reduces anti-predator behaviors in house finches. *J. Avian Biol.* **48**, 519–528 (2017).
26. S. R. Roberts, P. M. Nolan, G. E. Hill, Characterization of mycoplasma gallisepticum infection in captive house finches (*Carpodacus mexicanus*) in 1998. *Avian Dis.* **45**, 70–75 (2001).
27. P. M. Nolan, G. E. Hill, A. M. Stoehr, Sex, size, and plumage redness predict house finch survival in an epidemic. *Proc. Biol. Sci.* **265**, 961–965 (1998).
28. C. Bonneaud, S. L. Balenger, J. Zhang, S. V. Edwards, G. E. Hill, Innate immunity and the evolution of resistance to an emerging infectious disease in a wild bird. *Mol. Ecol.* **21**, 2628–2639 (2012).
29. C. Bonneaud *et al.*, Rapid antagonistic coevolution in an emerging pathogen and its vertebrate host. *Curr. Biol.* **28**, 2978–2983.e5 (2018).
30. M. Boots, Fight or learn to live with the consequences? *Trends Ecol. Evol.* **23**, 248–250 (2008).
31. M. R. Miller, A. White, M. Boots, The evolution of parasites in response to tolerance in their hosts: The good, the bad, and apparent commensalism. *Evolution* **60**, 945–956 (2006).
32. B. A. Roy, J. W. Kirchner, Evolutionary dynamics of pathogen resistance and tolerance. *Evolution* **54**, 51–63 (2000).
33. B. D. Inouye, Response surface experimental designs for investigating interspecific competition. *Ecology* **82**, 2696–2706 (2001).
34. N. Gotelli, A. Ellison, *A Primer of Ecological Statistics* (Sinauer Associates, Sunderland, MA, 2004).
35. G. V. Kollias *et al.*, Experimental infection of house finches with *Mycoplasma gallisepticum*. *J. Wildl. Dis.* **40**, 79–86 (2004).
36. S. Alizon, Y. Michalakis, Adaptive virulence evolution: The good old fitness-based approach. *Trends Ecol. Evol.* **30**, 248–254 (2015).
37. P. J. Kerr, Myxomatosis in Australia and Europe: A model for emerging infectious diseases. *Antiviral Res.* **93**, 387–415 (2012).
38. P. J. Kerr, S. M. Best, Myxoma virus in rabbits. *Rev. Sci. Tech.* **17**, 256–268 (1998).
39. M. J. Mackinnon, A. F. Read, Selection for high and low virulence in the malaria parasite *Plasmodium chabaudi*. *Proc. Biol. Sci.* **266**, 741–748 (1999).
40. A. E. Fleming-Davies *et al.*, Incomplete host immunity favors the evolution of virulence in an emergent pathogen. *Science* **359**, 1030–1033 (2018).
41. R. Froissart, J. Doumayrou, F. Vuillaume, S. Alizon, Y. Michalakis, The virulence-transmission trade-off in vector-borne plant viruses: A review of (non-)existing studies. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **365**, 1907–1918 (2010).
42. H. C. Leggett, C. K. Cornwallis, A. Buckling, S. A. West, Growth rate, transmission mode and virulence in human pathogens. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **372**, 20160094 (2017).
43. M. J. Mackinnon, A. F. Read, Virulence in malaria: An evolutionary viewpoint. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **359**, 965–986 (2004).
44. S. A. Frank, P. Schmid-Hempel, Mechanisms of pathogenesis and the evolution of parasite virulence. *J. Evol. Biol.* **21**, 396–404 (2008).
45. P. Schmid-Hempel, Parasite immune evasion: A momentous molecular war. *Trends Ecol. Evol.* **23**, 318–326 (2008).
46. S. M. Szczepanek *et al.*, Identification of lipoprotein MslA as a neoteric virulence factor of *Mycoplasma gallisepticum*. *Infect. Immun.* **78**, 3475–3483 (2010).
47. S. M. Szczepanek *et al.*, Comparative genomic analyses of attenuated strains of *Mycoplasma gallisepticum*. *Infect. Immun.* **78**, 1760–1771 (2010).
48. M. Staley, C. Bonneaud, Immune responses of wild birds to emerging infectious diseases. *Parasite Immunol.* **37**, 242–254 (2015).
49. I. Chambaud, H. Wróblewski, A. Blanchard, Interactions between mycoplasma lipoproteins and the host immune system. *Trends Microbiol.* **7**, 493–499 (1999).
50. H. D'Hauteville *et al.*, Two msbB genes encoding maximal acylation of lipid A are required for invasive *Shigella flexneri* to mediate inflammatory rupture and destruction of the intestinal epithelium. *J. Immunol.* **168**, 5240–5251 (2002).
51. M. W. Hornef, M. J. Wick, M. Rhen, S. Normark, Bacterial strategies for overcoming host innate and adaptive immune responses. *Nat. Immunol.* **3**, 1033–1040 (2002).
52. K. Ganapathy, J. M. Bradbury, Effects of cyclosporin A on the immune responses and pathogenesis of a virulent strain of *Mycoplasma gallisepticum* in chickens. *Avian Pathol.* **32**, 495–502 (2003).
53. J. E. Gaunson, C. J. Philip, K. G. Whithear, G. F. Browning, Lymphocytic infiltration in the chicken trachea in response to *Mycoplasma gallisepticum* infection. *Microbiology* **146**, 1223–1229 (2000).
54. J. E. Gaunson, C. J. Philip, K. G. Whithear, G. F. Browning, The cellular immune response in the tracheal mucosa to *Mycoplasma gallisepticum* in vaccinated and unvaccinated chickens in the acute and chronic stages of disease. *Vaccine* **24**, 2627–2633 (2006).
55. K. M. Lam, A. J. DaMassa, *Mycoplasma gallisepticum*-induced release of macrophage inflammatory protein-1 beta from chicken monocytes-macrophages. *J. Comp. Pathol.* **122**, 35–42 (2000).
56. J. Mohammed *et al.*, Chemokine and cytokine gene expression profiles in chickens inoculated with *Mycoplasma gallisepticum* strains Rlow or GT5. *Vaccine* **25**, 8611–8621 (2007).
57. K. Matsuo, K. Kuniyasu, S. Yamada, S. Susumi, S. Yamamoto, Suppression of immunoresponses to *Haemophilus gallinarum* with nonviable *Mycoplasma gallisepticum* in chickens. *Avian Dis.* **22**, 552–561 (1978).
58. C. J. Naylor, A. R. Al-Ankari, A. I. Al-Afaleq, J. M. Bradbury, R. C. Jones, Exacerbation of *Mycoplasma gallisepticum* infection in turkeys by rhinotracheitis virus. *Avian Pathol.* **21**, 295–305 (1992).
59. A. A. Dhondt, K. V. Dhondt, D. M. Hawley, C. S. Jennelle, Experimental evidence for transmission of *Mycoplasma gallisepticum* in house finches by fomites. *Avian Pathol.* **36**, 205–208 (2007).
60. M. Staley, C. Bonneaud, K. J. McGraw, C. M. Vleck, G. E. Hill, Detection of *Mycoplasma gallisepticum* in house finches (*Haemorrhous mexicanus*) from Arizona. *Avian Dis.* **62**, 14–17 (2018).
61. M. P. Luttrell, J. R. Fischer, D. E. Stallknecht, S. H. Kleven, Field investigation of *Mycoplasma gallisepticum* infections in house finches (*Carpodacus mexicanus*) from Maryland and Georgia. *Avian Dis.* **40**, 335–341 (1996).
62. S. R. Roberts, P. M. Nolan, L. H. Lauerman, L. Q. Li, G. E. Hill, Characterization of the mycoplasmal conjunctivitis epizootic in a house finch population in the southeastern USA. *J. Wildl. Dis.* **37**, 82–88 (2001).
63. L. Papazisi *et al.*, GapA and CrmA coexpression is essential for *Mycoplasma gallisepticum* cytoadherence and virulence. *Infect. Immun.* **70**, 6839–6845 (2002).
64. C. Bonneaud, S. L. Balenger, G. E. Hill, A. F. Russell, Experimental evidence for distinct costs of pathogenesis and immunity against a natural pathogen in a wild bird. *Mol. Ecol.* **21**, 4787–4796 (2012).
65. M. Staley, G. E. Hill, C. C. Josefson, J. W. Armbruster, C. Bonneaud, Bacterial pathogen emergence requires more than direct contact with a novel passerine host. *Infect. Immun.* **86**, 9 (2018).
66. J. L. Grodio, K. V. Dhondt, P. H. O'Connell, K. A. Schat, Detection and quantification of *Mycoplasma gallisepticum* genome load in conjunctival samples of experimentally infected house finches (*Carpodacus mexicanus*) using real-time polymerase chain reaction. *Avian Pathol.* **37**, 385–391 (2008).
67. R Core Team, *R: A Language and Environment for Statistical Computing* (Version 3.5.0, R Foundation for Statistical Computing, Vienna, Austria, 2016).
68. H. Wickham, *ggplot2: Elegant Graphics for Data Analysis* (Version 2.2.1, Springer, New York, 2009).
69. J. M. Ver Hoef, P. L. Boveng, Quasi-Poisson vs. negative binomial regression: How should we model overdispersed count data? *Ecology* **88**, 2766–2772 (2007).
70. A. Lindén, S. Mäntyniemi, Using the negative binomial distribution to model overdispersion in ecological count data. *Ecology* **92**, 1414–1421 (2011).